Ajinomoto Althea competitorsClear all

Oxford BioTherapeutics's top competitors include CytomX Therapeutics, ADC Therapeutics, Lexicon Pharmaceuticals and Anika Therapeutics.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Oxford BioTherapeutics
Oxford BioTherapeutics
Oxford BioTherapeutics develops medicines for cancer and companion diagnostics for selected antibody programs.
CytomX Therapeutics
CytomX Therapeutics
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
ADC Therapeutics
ADC Therapeutics
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
Anika Therapeutics
Anika Therapeutics
Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair.
Founding Date
Founding Date
2004
Founding Date
2008
Founding Date
2010
Founding Date
1995
Founding Date
1992
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Milton, GB HQ
San Jose, US
Locations
South San Francisco, US HQ
Locations
Epalinges, CH HQ
Greater London, GB
New Providence, US
San Mateo, US
Locations
The Woodlands, US HQ
Jersey, JE
Atlanta, US
Birmingham, US
Boston, US
Charlotte, US
Chicago, US
see more
Locations
Bedford, US HQ
Padova, IT
Padova, IT
Franklin, US
Employees
Employees
284% increase
Employees
15815% increase
Employees
1162% increase
Employees
20216% increase
Employees
15416% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
450.2 m
Valuation ($)
1.6 b
Valuation ($)
620.9 m
Valuation ($)
572.9 m
Twitter followers
Twitter followers
N/A
Twitter followers
963
Twitter followers
N/A
Twitter followers
259
Twitter followers
686
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
2
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
10
Number of tweets (last 30 days)
13
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
1.9
Average likes per tweet (last 30 days)
0.5
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
60%
Percentage of tweets with engagement (last 30 days)
38.46%
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
604494
Alexa Website Rank
281965
Alexa Website Rank
630173
Alexa Website Rank
164633
Employee Rating
Employee Rating
N/A
Employee Rating
3.3
Employee Rating
4.5
Employee Rating
3.5
Employee Rating
3.4

Financial

Revenue (est.)
Revenue (est.)
£2.1m (FY, 2018)
Revenue (est.)
$100.4m (FY, 2020)
Revenue (est.)
N/A
Revenue (est.)
$322.1m (FY, 2019)
Revenue (est.)
$130.5m (FY, 2020)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$3.2m (FY, 2019)
Cost of goods
$61.4m (FY, 2020)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$318.8m (FY, 2019)
Gross profit
$69m (FY, 2020)
Net income
Net income
(£6.5m) (FY, 2018)
Net income
($32.9m) (FY, 2020)
Net income
($246.3m) (FY, 2020)
Net income
$130.1m (FY, 2019)
Net income
($24m) (FY, 2020)

Operating

Patents (Foreign)
Patents (Foreign)
N/A
Patents (Foreign)
4 (FY, 2016)
Patents (Foreign)
N/A
Patents (Foreign)
N/A
Patents (Foreign)
151 (FY, 2016)
Patents (US)
Patents (US)
N/A
Patents (US)
13 (FY, 2016)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
21 (FY, 2016)
Patents Pending
Patents Pending
N/A
Patents Pending
144 (FY, 2016)
Patents Pending
N/A
Patents Pending
N/A
Patents Pending
14 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Pre-Clinical Phase Products
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
4 (FY, 2016)
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
1 (FY, 2016)
Pre-Clinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
$ 21.6m
Total funding raised
$ 132.4m
Total funding raised
$ 526m
Total funding raised
$ 244.7m
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

CytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase

CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.

View company
ADC Therapeutics
HQ
Epalinges, CH
Employees
116↑ 2% increase

ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.

View company
Lexicon Pharmaceuticals
HQ
The Woodlands, US
Employees
202↑ 16% increase

Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.

View company
Anika Therapeutics
HQ
Bedford, US
Employees
154↑ 16% increase

Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair.

View company